Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

Pages

13 results
11:19 AM, May 23, 2018  |  BC Innovations | Distillery Therapeutics

Transplant

normal DUSP6 expression. In mouse models of lymphoblastic leukemia and lymphoma receiving human and allogeneic melan-A
MLANA; MART1)-targeting CAR T cells, respectively, DUSP6 overexpression in the CAR T cells decreased GvHD-associated weight …
10:15 AM, Feb 28, 2018  |  BC Innovations | Distillery Techniques

Biomarkers

method scores blood samples from patients based on a signature of 19 transcripts -- including melan-A
MLANA; MART1), SRY-box containing gene 10 (SOX10), tyrosinase related protein 1 (TYRP1) and melanoma-associated chondroitin sulfate …
12:53 PM, Oct 12, 2017  |  BC Innovations | Translation in Brief

Opening doors for I-O

were associated with effective antitumor responses in patients receiving immunotherapy. In melanoma patients vaccinated with melan-A
MLANA ; MART1) peptide and the TLR9 agonist CpG7909 (PF-3512676), high serum VEGF-C concentrations were …
associated with large numbers of circulating MLANA-specific CD8 + T cells, which secreted pro-inflammatory cytokines. In …
12:40 PM, Oct 03, 2017  |  BC Innovations | Distillery Techniques

Biomarkers

immunotherapies in patients with solid tumors. In sera from 20 metastatic melanoma patients vaccinated with melan-A
MLANA ; MART1) peptide and the toll-like receptor 9 (TLR9) agonist CpG7909 , high VEGF-C …
concentrations were associated with large numbers of circulating MLANA-specific CD8 + T cells and high expression …
9:08 AM, Jun 07, 2017  |  BC Innovations | Distillery Techniques

Drug delivery

TRP-2 ; TYRP2) and a fusion of AIDA-I and the CD4 + T cell antigen melan-A
MLANA ; MART1) decreased tumor growth and increased CD4 + and CD8 + T cell …
12:00 AM, Apr 30, 2015  |  BC Innovations | Distillery Techniques

Techniques: Deoxycytidine kinase (DCK)-based in vivo PET imaging of T cell immunotherapies

T cells engineered to express the mutant DCK and a CAR against the melanoma antigen melan-A
MLANA ; MART1 ) gave a more intense PET imaging signal at tumor sites than …
12:00 AM, Jan 08, 2015  |  BC Innovations | Distillery Techniques

Techniques: Evolved T-cell receptor (TCR) variants

viral peptide-specific TCR were screened by yeast display and variants were identified that bound a Melan-A
In cell-based assays, soluble TCR variants achieved half-maximum staining of antigen-presenting cells (APCs) pre-loaded with Melan-A
12:00 AM, Feb 07, 2013  |  BC Innovations | Tools & Techniques

Rejuvenating T cells

led by Hiroshi Kawamoto, used a melanoma patient-derived T cell line expressing the melanoma epitope melan-A
MLANA ; MART1 ) to produce iPS cells. Nakauchi is professor and director at the …
CD8 + T cells generated from the melanoma cell line showed antigen-specific killing activity against melan-A
12:00 AM, Jan 31, 2013  |  BC Innovations | Distillery Techniques

Technology: Drug platforms

cells from a patient with melanoma to generate T cells that showed antigen-specific activity against melan-A
MLANA; MART1). Next steps for both groups include testing the regenerated human T cells in animal …
12:00 AM, Oct 25, 2012  |  BC Innovations | Cover Story

Melanoma's hidden act

and antigen loss. Indeed, T cells engineered to recognize GP100 or another melanocytic antigen called melan-A
MLANA ; MART1 ) showed less reactivity against human melanoma cells exposed to TNF-a than …

Pages